Yanwen Xie
Education
M.S., environmental health epidemiology, Harvard T.H. Chan School of Public Health; B.S. biotechnology, Sun Yat-sen University
Summary of Experience
Ms. Xie specializes in health economics and outcomes research (HEOR) with broad experience in real-world data (RWD) analysis and economic modeling. In her work, she uses data from clinical trials, administrative claims, disease registries, medical chart reviews, patient and physician surveys, and qualitative interviews. She is experienced in designing and conducting research to understand disease epidemiology and burden; treatment landscape; and patients’ clinical, economic, and humanistic outcomes. She also has extensive experience in cost-effectiveness analyses, budget impact analyses, and systematic literature reviews for health technology assessment (HTA) submissions in the UK, Europe, Canada, and Asia. Her research covers a broad range of therapeutic areas, including oncology, hematology, nephrology, autoimmune and inflammatory diseases, mental health disorders, and rare diseases. Ms. Xie’s work has been published in peer-reviewed journals and presented at clinical and economic research conferences.
-
Evolving Evidence-Based Value Assessment of One-Time Therapies: Tisagenlecleucel as a Case Study
Applied Health Economics and Health Policy, 2024
2024Laetsch T, Zhang J, Hongbo Yang H, Xie Y, Zhang D, Garrison L
-
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, Sun R, Kumar N, Wu EQ, Sullivan SD
-
Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
Transplantation and Cellular Therapy, 2021
2021Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, Yang H, Qi CZ, Chai X, Xie Y, Wu EQ, Igarashi A